drugset / Trial / NCT04301804

A Trial of SHR6390 in Healthy Caucasian Volunteers

NCT04301804

Phase 1 Completed 36 enrolled Atridia Pty Ltd.
RandomizedParallel-groupOpen-labelOther

Summary

This is a Phase 1, single center, single dose, open-label clinical study to evaluate the pharmacokinetics, safety and tolerability of SHR6390 under fasting conditions in healthy caucasian volunteers

Timeline

Start
2020-03-12
Primary completion
2020-05-28
Completion
2020-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalpiciclib Small molecule Oral

Indications

No indication recorded.